National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lynparza® is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.

Rapid Review

Commenced Completed Outcome
05/01/2015 19/02/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
17/08/2015 17/12/2015 Reimbursement Not Recommended

Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.